Jasper Therapeutics (JSPR) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

JSPR Jasper Therapeutics

Watchlist

5.550
-0.030-0.54%

Trading Mar 4 15:04 ET

83.37MMarket Cap-1.13P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $40 to $40
Moomoo NewsMar 4 08:00 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR) and Springworks Therapeutics (SWTX)
TipRanksMar 3 07:20 ET · Ratings
Positive Outlook on Jasper Therapeutics: Sustained Efficacy and Safety of Briquilimab in CSU Treatment
TipRanksMar 3 06:36 ET
Promising Outlook for Jasper Therapeutics: Buy Rating Amidst Potential Upside and Strategic Developments
TipRanksMar 3 05:56 ET · Ratings
Express News | Reported Saturday, Jasper Therapeutics Highlights Briquilimab's Safety And Efficacy In Phase 1b/2a BEACON Study Update At AAAAI 2025
BenzingaMar 3 02:56 ET
10-K: FY2024 Annual Report
SECFeb 28 09:21 ET · Announcements

Comments

Teddy123

Mar 2 09:38

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

$Jasper Therapeutics (JSPR.US)$
Can Jasper Therapeutics' Briquilimab Transform Chronic Urticaria Treatment? New Clinical Data Revealed

Jaguar8

Mar 1 11:46

NEWS 3/1

$Jasper Therapeutics (JSPR.US)$
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Saturday, 1st March at 12:45 pm
REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chro...